REGENXBIO
Update in progressRGNX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
REGENXBIO is a clinical‑stage biotechnology company developing gene therapies that deliver functional genes to cells with genetic defects using its NAV Technology Platform, an adeno-associated virus delivery system. Its pipeline includes ABBV-RGX-314 for wet AMD and retinal diseases, RGX-202 for Duchenne muscular dystrophy, RGX-121 for mucopolysaccharidosis type II, and RGX-111 for type I. It licenses NAV and collaborates with AbbVie and Nippon Shinyaku on these programs outside the U.S.
Company score
- Sentiment
- -0.25
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.04
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.08
- Governance
- -0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Curran M. Simpson M.S.
- Founded2008
- Employees371
- Websitewww.regenxbio.com
Identifiers
- ISINUS75901B1070
- FIGIBBG007Z9V591
- LEI549300EOES47LATSET33
- CUSIP75901B107
- CIK0001590877